Sea Lane Biotechnologies LLC
Assembling antibodies with modular components, by the billions
This article was originally published in Start Up
Executive Summary
Sea Lane Biotechnologies LLC’s original goal was to leverage the immunological repertoire of flu epidemic survivors by harvesting bone marrow and screening for natural antibodies that could then be developed into drugs, but the human-derived antibodies that Sea Lane gathered in its early days contributed to a new technology platform. Sea Lane thinks its technology, called ConCIRT, for Contextual Immune Repertoire Technology, will prove capable of generating novel treatments for cancer and potentially other non-infectious diseases.